Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 1.00 |
| ▸ | GRN | P28799 | 7/20 | 0.65 |
| ▸ | SORT1 | Q99523 | 7/20 | 0.65 |
| ▸ | TASP1 | Q9H6P5 | 1/20 | 0.64 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.51 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | SLC16A3 | O15427 | 2/20 | 0.49 |
| ▸ | SLC16A1 | P53985 | 2/20 | 0.49 |
| ▸ | MCTS1 | Q9ULC4 | 2/20 | 0.49 |
| ▸ | CRHBP | P24387 | 1/20 | 0.49 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1898696 | 0.84 | TASP1 (0.81) | NPC1GRNSORT1TASP1NPSR1 | |
| SCHEMBL1899805 | 0.84 | NPC1 (0.72) | NPC1TASP1NPSR1MAPTCRHBP | |
| SCHEMBL1900846 | 0.83 | NPC1 (0.70) | NPC1GRNSORT1TASP1NPSR1 | |
| SCHEMBL17727586 | 0.82 | NPC1 (0.69) | NPC1NPSR1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL1898992 | 0.81 | NPC1 (0.68) | NPC1TASP1NPSR1MAPTCRHBP | |
| SCHEMBL1899142 | 0.81 | NPC1 (0.67) | NPC1GRNSORT1TASP1NPSR1 | |
| SCHEMBL13990277 | 0.80 | NPC1 (0.67) | NPC1TASP1NPSR1CYP1A2CYP3A4 | |
| SCHEMBL13990665 | 0.80 | NPC1 (0.67) | NPC1GRNSORT1TASP1NPSR1 | |
| SCHEMBL24283481 | 0.79 | GRN (1.00) | NPC1GRNSORT1NPSR1MAPT | |
| SCHEMBL1903539 | 0.79 | TASP1 (0.65) | NPC1TASP1NPSR1MAPTCRHBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7790761-B2 | Blockade of voltage dependent sodium channels | UNIVERSITY COLLEGE LONDON (GB) | 2010-09-07 | — | — | US | disclosed |
| US-20060100248-A1 | Blockade of voltage dependent sodium channels | GARTHWAITE GITI | 2006-05-11 | — | — | US | disclosed |
| US-7009056-B2 | Blockade of voltage dependent sodium channels | UNIVERSITY COLLEGE LONDON (GB) | 2006-03-07 | — | — | US | disclosed |
| US-20030171403-A1 | Blockade of voltage dependent sodium channels | UNIVERSITY COLLEGE LONDON (GB) | 2003-09-11 | — | — | US | disclosed |
| EP-1252156-A1 | BLOCKADE OF VOLTAGE DEPENDENT SODIUM CHANNELS | University College London (GB) | 2002-10-30 | — | — | EP | disclosed |
| WO-2001057024-A1 | BLOCKADE OF VOLTAGE DEPENDENT SODIUM CHANNELS | UNIVERSITY COLLEGE LONDON (GB) | 2001-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030171403-A1 | Blockade of voltage dependent sodium channels | CACNA1F, SCNN1B, CACNA1B | NPC1 970/4885GRN 2010/4885SORT1 2444/4885 |
| US-20060100248-A1 | Blockade of voltage dependent sodium channels | CACNA1I, CACNA1F, CACNA1C | NPC1 1008/4885GRN 1919/4885SORT1 2364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.